New Delhi, February 19, 2025: Leucine Rich Bio, South Asia’s first Microbiome company and a leader in microbiome research and healthcare solutions is proud to announce that it has been awarded the ISO/IEC 17025:2017 certification. This prestigious recognition marks a significant milestone, as Leucine Rich Bio becomes the first microbiome company in South Asia to receive this international certificate.
The company has already been certified with ISO 9001:2015, demonstrating its commitment to maintaining high standards in quality management systems. The new ISO 17025:2017 accreditation further underscores Leucine Rich Bio’s dedication to excellence, particularly in the realm of instrument management, including proper and regular calibrations.
ISO/IEC 17025:2017 is the internationally recognized standard for the competence of testing and calibration laboratories. Over the years, Leucine Rich Bio has been at the forefront of microbiome innovation, with achievements such as the launch of the renowned BugSpeaks microbiome test and several awards, including the National Startup Award and Frost & Sullivan recognition for genomics and microbiome diagnostics.
Dr. Debojyoti Dhar, Co-founder and Director of Leucine Rich Bio, expressed his pride in the achievement. He stated, “This certification reflects our team’s hard work and dedication in ensuring that our solutions meet the highest global standards. At Leucine Rich Bio, we remain committed to pushing the boundaries of innovation in healthcare, leveraging data analytics and research to improve health outcomes. This milestone strengthens our position as a trusted name in microbiome research and healthcare solutions.”
Leucine Rich Bio continues to lead the way in microbiome research, with a focus on innovation and excellence. The company remains dedicated to advancing scientific knowledge and improving health outcomes through their cutting-edge research and products. With the ISO 17025:2017 accreditation, Leucine Rich Bio is poised to further solidify its position as a leader in the microbiome industry, both in South Asia and globally.